Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib

In advanced HCC, tyrosine-kinase inhibitors obtain partial responses (PR) in some patients and complete responses (CR) in a few. Better understanding of the mechanism of response could be achieved by the radiomic approach combining digital imaging and serological biomarkers (α-fetoprotein, AFP and p...

Full description

Bibliographic Details
Main Authors: Piero Colombatto, Coskun Ozer Demirtas, Gabriele Ricco, Luigi Civitano, Piero Boraschi, Paola Scalise, Daniela Cavallone, Filippo Oliveri, Veronica Romagnoli, Patrizia Bleve, Barbara Coco, Antonio Salvati, Lucio Urbani, Ferruccio Bonino, Maurizia Rossana Brunetto
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
HCC
sorafenib
regorafenib
AFP
PIVKA-II
Online Access:https://www.mdpi.com/2072-6694/13/9/2064

Internet

https://www.mdpi.com/2072-6694/13/9/2064

Similar Items